AI Article Synopsis
- The study reports the development and testing of four derivatives of 3-hydroxy-piperidine-N-benzyl-aryl-acylhydrazone for their pain-relief potential.
- Compounds 6a and 6d demonstrated significant pain relief in the tail flick test and increased pain threshold in a neuropathic pain model.
- The pain relief effects of these compounds were reversible with naloxone, indicating they work through an opioid mechanism without causing sedation or impairing motor skills.
Article Abstract
Here in, we report the preparation and evaluation of four 3-hydroxy-piperidine-N-benzyl-aryl-acylhydrazone derivatives (6a-d) for their potential antinociceptive activity. In the tail flick test, compounds 6a and 6d exhibited a significant increase in the latency time of the animals, in comparison to the control group. These two compounds also showed a significant increase in the nociceptive threshold from 1 to 6 h after treatment in the CCI neuropathic pain model. In both cases, the antinociceptive activity was blocked by naloxone, suggesting an opioid mechanism of action, but without sedative or motor coordination effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2018.01.077 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!